

Fred

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8825847/publications.pdf>

Version: 2024-02-01

13
papers

1,748
citations

933447

10
h-index

1199594

12
g-index

13
all docs

13
docs citations

13
times ranked

1068
citing authors

#	ARTICLE	IF	CITATIONS
1	The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine. <i>Neurotherapeutics</i> , 2022, 19, 922-930.	4.4	15
2	Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale. <i>BioDrugs</i> , 2022, 36, 341-358.	4.6	18
3	Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations. <i>Therapeutics and Clinical Risk Management</i> , 2022, Volume 18, 447-456.	2.0	4
4	Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine. <i>Pain Medicine</i> , 2021, 22, 1857-1863.	1.9	33
5	A randomized study of IV prochlorperazine plus diphenhydramine versus IV hydromorphone for migraine-associated symptoms: A post hoc analysis. <i>Headache</i> , 2021, 61, 1227-1233.	3.9	1
6	Indeterminate Serotonin Release Assays Are Associated with a High Mortality Rate. <i>Blood</i> , 2020, 136, 12-13.	1.4	0
7	Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review. <i>Headache</i> , 2019, 59, 20-32.	3.9	71
8	Basic Considerations for the Use of Monoclonal Antibodies in Migraine. <i>Headache</i> , 2018, 58, 1689-1696.	3.9	22
9	Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1999.	7.4	379
10	Fremanezumab for the Preventive Treatment of Chronic Migraine. <i>New England Journal of Medicine</i> , 2017, 377, 2113-2122.	27.0	573
11	Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. <i>Lancet Neurology</i> , The, 2015, 14, 1081-1090.	10.2	236
12	Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. <i>Lancet Neurology</i> , The, 2014, 13, 1100-1107.	10.2	333
13	Why Substitution Enhances the Reactivity of LiFePO_4 . <i>Chemistry of Materials</i> , 2013, 25, 85-89.	6.7	63